Drug
Pirfenidone (Esbriet®, Pirfenex®, Pirespa®)
Status:
To Patients
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Pirfenidone (Esbriet®, Pirfenex®, Pirespa®) is an antifibrotic and anti-inflammatory drug approved to treat IPF in the US, Europe, Canada, Asia, and Australia. In clinical trials, pirfenidone has been shown to slow progression of mild-to-moderate idiopathic pulmonary fibrosis. It is taken by mouth three times a day.